INTRODUCTION {#sec1-1}
============

Estrogens control the growth and differentiation of mammary glands and regulate gene expression in breast cells through the estrogen receptor (ER). ERs are expressed in 70% of breast cancer cases where cancer cell growth is controlled by estrogen and is often susceptible to treatment with inhibitors that block the interaction between estrogen and the estrogen receptor.

The estrogen receptor status in breast cancer plays a major role in the progression and metastatic potential of breast cancer in women. Breast cancer cells lacking the (ER−) are usually more advanced and more difficult to treat than ER+ breast cancer cells. A disparity in breast carcinoma survival between ER− and ER+ cases has been noted over the past several decades. ER− women have more advanced breast cancer at the time of diagnosis than ER+ women. In addition, ER− women tend to have breast cancer tumor types that are more aggressive and have poorer prognosis. ER− breast cancer cells in women, regardless of age, are more likely to have tumor grade III or IV with fewer grade I and II tumor stages combined and for each individual stage group.

Epidemiologic studies have found a significant correlation between ER+ breast cancer cells and several lifestyle risk factors, such as higher body mass index, earlier age at menarche, nulliparity, and diet.\[[@CIT1]--[@CIT3]\] Cho *et al.* studied the association between dietary fat intake and breast cancer in premenopausal women and found a strong correlation between fat intake and the elevated risk of ER+ breast cancers.\[[@CIT4]\]

A case-case study that evaluated the association of dietary fat intake of selected fatty acids found that high intakes of linoleic acid in premenopausal breast cancer patients were associated with a threefold higher risk of ER− than ER+ tumors.\[[@CIT5]\]

The disparities observed in incidence trends and age at diagnosis highlight the need for further investigation of the differences between ER− and ER+ breast cancer cells. Gruvberger *et al.* studied gene expression profiles in ER− and ER+ breast tumors using microarrays and showed that they had very distinct gene expression patterns.\[[@CIT6]\] The study found a significant increase in the expression levels of *P-cadherin*, *C/EBP* β transcription factor, and *ladinin* in ER− breast cancer cells. It also identified *GATA3*, *Cyclin D1* and *carbonic anhydrase XII* expression to be associated with ER+ breast cancer samples.

In a previous study, we characterized the transcriptional profiles in breast cancer cells treated with omega-3 and omega-6 fatty acids.\[[@CIT7]\] In that study, we observed differences in gene expression between ER+ and ER− cells in response to the fatty acids, but this was a preliminary finding since only 2 cell lines of each ER status were used; therefore we doubled the number of each group in order to identify gene expression profiles directly associated with ER status. We are now able to describe in more detail the role of ER status on the gene expression in breast cancer cells in response to omega-3 and omega-6 fatty acids using the 4 well-characterized ER− and 4 ER+ breast cancer cells. We identified the genes that were significantly correlated with the ER status when breast cancer cells were treated with these fatty acids.

Note: microarray data have been submitted to the Gene Expression Omnibus (GEO) and can be searched using the Platform ID: GPL8144, Series: GSE14679.

MATERIALS AND METHODS {#sec1-2}
=====================

ER− (HCC-1806, MDA-MB-468, Hs578T and SK-BR-3) and ER+ (HCC-70, MCF-7, HCC-1500 and CAMA-1) breast cancer cell lines as well as culture media were obtained from ATCC (Manassass, VA). Fatty acids were obtained from BioMol (Plymouth Meeting, PA). Each fatty acid was aliquoted and aliquots were stored at -70°C until used. The TRIzol™ reagent was obtained from Invitrogen (Carlsbad, CA), iScript cDNA synthesis kit from Bio-Rad (Hercules, CA) and the Micromax Tyramide Signal Amplification (TSA) and Labeling Kit from Perkin Elmer, Inc. (Wellesley, MA).

Cell lines were cultured in the recommended media. Twenty four hours prior to treatment with fatty acids, culture media were removed and cells were washed with PBS and incubated in the same media supplemented with 1% (v/v) insulin/sodium selenite and 1% (v/v) non-essential amino acids in the absence of FBS. At the scheduled times, selected flasks were treated with 10 *μ*M fatty acids added to fresh media and incubated for six and 24 hours respectively. Control cells were incubated in fresh media in the absence of fatty acids.

Total RNA was isolated using TRIzol reagent (Invitrogen, CA) following the manufacturer\'s protocol. RNA quality and quantity were determined on an Agilent 2100 Bioanalyzer (Agilent Technologies, CA).

Human cDNA microarrays were prepared as described in Hammamieh *et al.*\[[@CIT8]\] Briefly, we used sequence verified oligos (∼36,000 oligos) representing the whole genome (Operon, Inc, Huntsville, AL). The oligos were deposited in 3X saline sodium citrate (SSC) at an average concentration of 165 βg/ml on CMT-GAPS II aminopropyl silane-coated slides (Corning, NY), using a VersArray microarrayer (Bio-Rad, Inc). Arrays were post processed using UV-cross linking at 1200 mJ/cm^2^ and by baking for four hours at 80°C. Positively charged amine groups (on the slide surface) were then treated with succinic anhydride and N-methyl-2-pyrrolidinone.

Microarray slides were labeled using Micromax Tyramide Signal Amplification (TSA) Labeling and Detection Kit (Perkin Elmer, Inc., MA) as described in Hammamieh *et al*.\[[@CIT7]\] Slides were hybridized for 16 hours at 60 °C. Hybridized slides were scanned using GenePix Pro 4000B optical scanner (Axon Instruments, Inc., CA). Intensities of the scanned images were digitalized through Genepix 6.0 software.

Assessment of the overall integrity of the microarray experiment were carried out as described in Hammamieh *et al*:\[[@CIT8]\]

Microarray images were visualized and normalized using ImaGene 6.0 (BioDiscovery, Inc., CA); and data was analyzed using GeneSpring 10.1 (Agilent Technologies, CA).

Background and foreground pixels of each spot were segmented using ImaGene (BioDiscovery Inc., CA), and the highest and lowest 20% groups of the probe intensity were discarded. Local background correction was applied to each individual spot. The genes that passed this filter in all the experiments were further analyzed.

Data filter and statistical analysis were carried out using GeneSpring 10.1. Local background was subtracted from individual spot intensity and genes that failed 'background check' in any of the experiments were eliminated from further analysis. Each chip was next subjected to intra-chip normalization (LOWESS). Differentially regulated genes (between control and treated sample sets) were selected using *t*-test analysis (P \< 0.05).

Principal component analysis (PCA) was performed over the given dataset, classifying each sample as a statistical variable in order to confirm the extent of variability within the sample classes and among the pre-designed groups. A two-dimensional hierarchal clustering calculation using Pearson correlation around zero was also performed.

We randomly selected genes to confirm their expression profiles using real time PCR. These genes are *Protocadherin, thyroid hormone receptor-associated protein complex component (TRAP150), Mitochondrial ribosomal protein L43, transducer of ERBB2, WNT-2B Isoform 1 oncogene and coiled-coil domain containing 61 (CCDC61).* Primer3, A web-based primer designing tool, was used to design primers for selected genes (<http://www.frodo.wi.mit.edu/>). The specificity of each primer sequence was confirmed by running a blast search. Reverse transcription and Real-time PCR reactions were carried out using iScript cDNA synthesis kit from Bio-Rad (Hercules, CA) and a Real-time PCR kit (Roche, IN), respectively. Each reaction was run in I-Cycler (Bio-Rad, CA) using five technical duplicates. Each sample was also amplified using primer sets for the 18S house-keeping probe of the experiment. The resultant cycle threshold data from each real-time-PCR 'run' was converted to fold-change.

RESULTS {#sec1-3}
=======

We have studied gene expression profiles and identified genes differentially expressed between ER− and ER+ breast cancer cells treated with EPA.

Data were normalized by applying inter-chip and intra-chip normalizations using GeneSpring 10.1, as described in the methods section. When we used One-way ANOVA with a P-value \< 0.05 we identified 819 genes, out of the 36000 genes, to be differentially expressed between ER− and ER+ breast cancer cells in response to treatment with EPA \[[Figure 1](#F0001){ref-type="fig"}\].

![A pseudo color cluster view of genes differentially expressed between ER− and ER+ breast cancer cells in response to EPA. Cells were treated with EPA at 6 and 24 hrs. RNA was isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g001){#F0001}

To functionally classify the genes associated with the ER status in breast cancer cells treated with EPA, we used GeneSpring 10.1 and FATIGO+.\[[@CIT9][@CIT10]\] We have also used Ingenuity Pathway Analysis and GeneCite to carry out detailed pathway analysis using the Biocarta pathways.\[[@CIT11]\] Functional classification of up regulated genes revealed that genes involved in the G2/M DNA damage checkpoint regulation, protein ubiquitination and apoptosis signaling were up regulated in ER+ cells in response to EPA while the cyclin dependent kinase signaling cascade was associated with ER− cells.

Ingenuity analysis of the genes up regulated in ER+ cells identified an apoptosis related network as being significantly enriched and among the top ranked networks. Some of these genes included caspases and STAT1. They are listed in [Table 1](#T0001){ref-type="table"} and a simplified network is depicted in [Figure 2](#F0002){ref-type="fig"}. Hypoxia-inducible factor 1 (HIF1-α), hypoxia inducible factor 3(HIF3-α) DEAD (Asp-Glu-Ala-Asp) box polypeptide 21, CHK1 checkpoint homolog, cyclin-dependent kinase inhibitor 2A (CDKN2A) and the CDKN2A interacting protein (CDKN2AIP) were also uniquely up regulated in ER+ cells \[[Table 2](#T0002){ref-type="table"}\].

###### 

Apoptosis related genes up regulated in ER+ breast cancer cells in response to EPA

  Symbol   Entrez gene name                                            Fold change
  -------- ----------------------------------------------------------- -------------
  CASP4    caspase 4, apoptosis-related cysteine peptidase             3.5
  CLSPN    claspin homolog (Xenopus laevis)                            1.8
  DDX58    DEAD (Asp-Glu-Ala-Asp) box polypeptide 58                   5.0
  DSG1     desmoglein 1                                                2.7
  PABPC1   poly(A) binding protein, cytoplasmic 1                      1.5
  PAWR     PRKC, apoptosis, WT1, regulator                             4.0
  PHIP     pleckstrin homology domain interacting protein              2.1
  RAD21    RAD21 homolog (S. pombe)                                    2.0
  RNF7     ring finger protein 7                                       1.3
  RPL36    ribosomal protein L36                                       1.2
  STAT1    signal transducer and activator of transcription 1, 91kDa   1.5
  TAC1     tachykinin, precursor 1                                     1.6
  WAPAL    wings apart-like homolog (Drosophila)                       1.9

![Ingenuity pathway analysis and expression profiles of genes involved in apoptosis that were uniquely up regulated in ER+ cells in response to EPA. Cells were incubated with EPA for 6 and 24 hrs. RNA samples were isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g002){#F0002}

###### 

HIF Pathway related genes up regulated in ER+ breast cancer cells in response to EPA

  Symbol      Entrez gene name                                                      Fold change
  ----------- --------------------------------------------------------------------- -------------
  ARNT        aryl hydrocarbon receptor nuclear translocator                        2.0
  SFRS1       splicing factor, arginine/serine-rich 1                               1.2
  DDX3X       DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked                    1.5
  RPL8        ribosomal protein L8                                                  1.5
  HNRNPM      heterogeneous nuclear ribonucleoprotein M                             1.5
  HNRNPA2B1   heterogeneous nuclear ribonucleoprotein A2/B1                         1.5
  DACH1       dachshund homolog 1 (Drosophila)                                      1.6
  HIF1A       hypoxia-inducible factor 1, alpha subunit                             1.7
  NRN1        neuritin 1                                                            1.7
  HDGF        hepatoma-derived growth factor (high-mobility group protein 1-like)   1.8
  CDKN2A      cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)   1.8
  CLSPN       claspin homolog (Xenopus laevis)                                      1.8
  RBM39       RNA binding motif protein 39                                          1.8
  NUP50       nucleoporin 50kDa                                                     1.8
  HIF3A       hypoxia inducible factor 3, alpha subunit                             1.9
  CDKN2AIP    CDKN2A interacting protein                                            2.1
  DDX21       DEAD (Asp-Glu-Ala-Asp) box polypeptide 21                             2.2
  CHEK1       CHK1 checkpoint homolog (S. pombe)                                    2.4
  DSG1        desmoglein 1                                                          2.7
  NPM1        nucleophosmin (nucleolar phosphoprotein B23, numatrin)                2.8

Our data show that genes involved in cell-to-cell signaling were up regulated only in ER− cells when treated with EPA. These genes include the Cyclin-dependent kinase 4 (CDK4), cell division cycle 7 (CDC7), cyclin-dependent kinase 4, fragile X mental retardation 1, protein phosphatase 1 catalytic subunit beta isoform (PPP1CB), protein phosphatase 1 regulatory (inhibitor) subunit 12A (PPP1R12A), protein phosphatase 2 catalytic subunit alpha isoform (PPP2CA) and protein phosphatase 2 regulatory subunit A alpha isoform (PPP2R1A).

Among the genes that were down regulated in ER+ cells in response to EPA were genes involved in β-catenin signaling and the BCL-2 anti-apoptosis pathway \[[Figure 3](#F0003){ref-type="fig"}\]. [Table 3](#T0003){ref-type="table"} lists the name and the regulation patterns of genes involved in the β-catenin pathway.

![β-catenin cascade that was uniquely down regulated in ER+ cells in response to EPA. Cells were incubated with EPA for 6 and 24 hrs. RNA samples were isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g003){#F0003}

###### 

Beta-catenin signaling and the BCL-2 antiapoptosis pathway genes down regulated in ER+ cells in response to EPA

  Symbol     Entrez Gene Name                                                                 Fold Change
  ---------- -------------------------------------------------------------------------------- -------------
  AGRN       agrin                                                                            −2.0
  BARX2      BARX homeobox 2                                                                  −1.6
  BIN1       bridging integrator 1                                                            −2.4
  BTK        Bruton agammaglobulinemia tyrosine kinase                                        −2.6
  CLU        clusterin                                                                        −2.4
  CREB1      cAMP responsive element binding protein 1                                        −1.1
  CTNNB1     catenin (cadherin-associated protein), beta 1, 88kDa                             −1.5
  DLG1       discs, large homolog 1 (Drosophila)                                              −1.5
  DVL3       dishevelled, dsh homolog 3 (Drosophila)                                          −3.7
  FHL2       four and a half LIM domains 2                                                    −2.1
  FOXO3      forkhead box O3                                                                  −2.3
  GPR124     G protein-coupled receptor 124                                                   −1.5
  GRB14      growth factor receptor-bound protein 14                                          −1.4
  HIST1H1E   histone cluster 1, H1e                                                           −1.6
  IQGAP2     IQ motif containing GTPase activating protein 2                                  −5.2
  KCNAB1     potassium voltage-gated channel, shakerrelated subfamily, beta member 1          −1.7
  KCNJ2      potassium inwardly-rectifying channel, subfamily J, member 2                     −2.1
  L1CAM      L1 cell adhesion molecule                                                        −10.6
  LMNA       lamin A/C                                                                        −1.1
  LMO2       LIM domain only 2 (rhombotin-like 1)                                             −1.6
  LRP5       low density lipoprotein receptor-related protein 5                               −2.0
  MAGED1     melanoma antigen family D, 1                                                     −1.6
  MYH9       myosin, heavy chain 9, non-muscle                                                −100.0
  NR5A2      nuclear receptor subfamily 5, group A, member 2                                  −1.2
  PIGC       phosphatidylinositol glycan anchor biosynthesis, class C                         −1.5
  PTPN1      protein tyrosine phosphatase, non-receptor type 1                                −1.7
  PTPN5      protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched)            −1.9
  RPS6KA4    ribosomal protein S6 kinase, 90kDa, polypeptide 4                                −1.6
  SDF4       stromal cell derived factor 4                                                    −2.4
  SMARCA4    SWI/SNF related, actin dependent regulator of chromatin, subfamily a, member 4   −2.9
  SMARCE1    SWI/SNF related, actin dependent regulator of chromatin, subfamily e, member 1   −1.0
  SNX9       sorting nexin 9                                                                  −3.8
  STXBP1     syntaxin binding protein 1                                                       −1.4
  SYNJ2      synaptojanin 2                                                                   −1.2

The genes of amino acid synthesis pathway were highly enriched in the list of genes down regulated by EPA in ER− cells. These genes are listed in [Table 4](#T0004){ref-type="table"}. We have studied gene expression profiles and identified genes differentially expressed between ER− and ER+ breast cancer cells treated with AA.

###### 

Amino acid synthesis related genes down regulated in ER- cells in response to EPA

  Symbol    Entrez Gene Name                                                      Fold Change
  --------- --------------------------------------------------------------------- -------------
  BMPR1B    bone morphogenetic protein receptor, type IB                          −1.3
  CYP1A2    cytochrome P450, family 1, subfamily A, polypeptide 2                 −8.3
  DR1       down-regulator of transcription 1, TBPbinding (negative cofactor 2)   −1.4
  ECOP      EGFR-coamplified and overexpressed protein                            −1.6
  GRIN3A    glutamate receptor, ionotropic, N-methyl-Daspartate 3A                −1.7
  HK1       hexokinase 1                                                          −1.5
  HGFAC     HGF activator                                                         −4.5
  IHPK1     inositol hexaphosphate kinase 1                                       −1.8
  IL1R2     interleukin 1 receptor, type II                                       −5.2
  KLHL1     kelch-like 1 (Drosophila)                                             −3.9
  KITLG     KIT ligand                                                            −1.1
  MAP3K5    mitogen-activated protein kinase kinase kinase 5                      −1.1
  PAX4      paired box 4                                                          −1.3
  POLDIP3   polymerase (DNA-directed), delta interacting protein 3                −1.2
  PPP2R1B   protein phosphatase 2, regulatory subunit A, beta isoform             −3.5
  ROR2      receptor tyrosine kinase-like orphan receptor 2                       −1.8
  ARHGEF5   Rho guanine nucleotide exchange factor (GEF) 5                        −2.7
  RBM16     RNA binding motif protein 16                                          −6.5
  SAFB      scaffold attachment factor B                                          −1.6
  SMPD2     sphingomyelin phosphodiesterase 2, neutral membrane                   −1.7
  TARBP1    TAR (HIV-1) RNA binding protein 1                                     −2.2
  TGFA      transforming growth factor, alpha                                     −1.2
  TUBA1A    tubulin, alpha 1a                                                     −1.8
  WDR68     WD repeat domain 68                                                   −1.5

When we used One-way ANOVA with a P-value \< 0.05 we identified 437 genes to be differentially expressed between ER− and ER+ breast cancer cells in response to treatment with AA \[[Figure 4](#F0004){ref-type="fig"}\].

![A pseudo color cluster view of genes differentially expressed between ER− and ER+ breast cancer cells in response to AA. Cells were treated with AA at 6 and 24 hrs. RNA was isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g004){#F0004}

Functional annotation of the genes differentially up regulated in ER− and ER+ cells showed that ERK/MAPK, NF-κB, EGF signaling and VEGF signaling cascades were highly enriched in ER+ cells treated with Arachidonic acids while in ER− cells RAR Activation cascade, IL-4 signaling, insulin receptor signaling, and p53 signaling were significantly expressed.

Functional annotation and pathway analysis of genes up regulated mainly in ER+ breast cancer cells in response to Arachidonic acid show that the top ranked pathway was the ERK/MEK signaling pathway \[[Figure 5](#F0005){ref-type="fig"}\]. [Table 5](#T0005){ref-type="table"} lists the genes from the ERK- pathway that were up regulated by Arachidonic acid in ER+ breast cancer cells.

![Ingenuity pathway analysis of genes up regulated in ER+ cell in response to AA shows that the ERK/MEK pathway was significantly associated with ER+. Cells were treated with AA at 6 and 24 hrs. RNA was isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g005){#F0005}

###### 

ERK pathway related genes up regulated in ER+ breast cancer cells in response to AA

  Symbol    Entrez Gene Name                                                                   Fold Change
  --------- ---------------------------------------------------------------------------------- -------------
  ABI1      abl-interactor 1                                                                   2.9
  AKAP1     A kinase (PRKA) anchor protein 1                                                   2.6
  ARHGEF7   Rho guanine nucleotide exchange factor (GEF) 7                                     3.0
  BAD       BCL2-associated agonist of cell death                                              2.1
  CCDC6     coiled-coil domain containing 6                                                    2.7
  CRP       C-reactive protein, pentraxin-related                                              2.8
  CX3CL1    chemokine (C-X3-C motif) ligand 1                                                  2.3
  CXCR4     chemokine (C-X-C motif) receptor 4                                                 2.4
  EGF       epidermal growth factor (beta-urogastrone)                                         2.0
  EGFR      epidermal growth factor receptor                                                   3.4
  ELF3      E74-like factor 3 (ets domain transcription factor, epithelial-specific)           2.4
  EPHB4     EPH receptor B4                                                                    2.1
  FIGF      c-fos induced growth factor (vascular endothelial growth factor D)                 2.4
  GAB1      GRB2-associated binding protein 1                                                  2.5
  GIT2      G protein-coupled receptor kinase interacting ArfGAP 2                             2.9
  HSPD1     heat shock 60kDa protein 1 (chaperonin)                                            2.4
  KLF5      Kruppel-like factor 5 (intestinal)                                                 3.9
  MATK      megakaryocyte-associated tyrosine kinase                                           2.9
  MCAM      melanoma cell adhesion molecule                                                    2.8
  MUC1      mucin 1, cell surface associated                                                   3.9
  NCK1      NCK adaptor protein 1                                                              3.1
  P2RY6     pyrimidinergic receptor P2Y, G-protein coupled, 6                                  2.7
  PIK3CB    phosphoinositide-3-kinase, catalytic, beta polypeptide                             2.6
  PIK3R3    phosphoinositide-3-kinase, regulatory subunit 3 (gamma)                            3.9
  PITPNM3   PITPNM family member 3                                                             2.0
  PLA2G2A   phospholipase A2, group IIA (platelets, synovial fluid)                            12.2
  PLCG2     phospholipase C, gamma 2 (phosphatidylinositol-specific)                           3.2
  PPM1E     protein phosphatase 1E (PP2C domain containing)                                    4.5
  PPP1CA    protein phosphatase 1, catalytic subunit, alpha isoform                            2.5
  PTK2B     PTK2B protein tyrosine kinase 2 beta                                               3.0
  PTPN12    protein tyrosine phosphatase, non-receptor type 12                                 4.3
  PXN       paxillin                                                                           10.8
  RHOU      ras homolog gene family, member U                                                  2.3
  RPS27A    ribosomal protein S27a                                                             2.7
  RPS6KA1   ribosomal protein S6 kinase, 90kDa, polypeptide 1                                  2.4
  SH3KBP1   SH3-domain kinase binding protein 1                                                2.9
  SHKBP1    SH3KBP1 binding protein 1                                                          2.3
  SORBS2    sorbin and SH3 domain containing 2                                                 10.9
  SOS1      son of sevenless homolog 1 (Drosophila)                                            3.6
  STAT3     signal transducer and activator of transcription 3 (acute-phase response factor)   2.1
  TMOD1     tropomodulin 1                                                                     5.0
  TRIM29    tripartite motif-containing 29                                                     11.9

We carried out functional annotation for the genes that were up regulated in ER− cells when treated by Arachidonic acid and found that the Insulin Receptor signaling pathway was highly enriched. Vascular endothelial growth factor and superoxide dismutase were also up regulated in ER− cells \[[Figure 6](#F0006){ref-type="fig"}\]. [Table 6](#T0006){ref-type="table"} lists the insulin receptor pathway genes that were uniquely up regulated in ER− cells.

![The insulin receptor cascade was uniquely up regulated in ER− cells when treated with AA. Ingenuity pathway analysis of the insulin receptor cascade showing the expression patterns of the pathway component in ER− cells. Cells were treated with AA at 6 and 24 hrs. RNA was isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g006){#F0006}

###### 

Insulin receptor pathway related genes up regulated in ER- breast cancer cells in response to AA

  Symbol    Entrez gene name                                                            Fold change
  --------- --------------------------------------------------------------------------- -------------
  ADIPOQ    adiponectin, C1Q and collagen domain containing                             3.4
  BTK       Bruton agammaglobulinemia tyrosine kinase                                   54.9
  CDK2      cyclin-dependent kinase 2                                                   2.4
  CSF3R     colony stimulating factor 3 receptor (granulocyte)                          2.1
  CTGF      connective tissue growth factor                                             2.1
  CTSD      cathepsin D                                                                 2.2
  ESR2      estrogen receptor 2 (ER beta)                                               2.5
  GRB2      growth factor receptor-bound protein 2                                      2.3
  HAS2      hyaluronan synthase 2                                                       2.0
  HBEGF     heparin-binding EGF-like growth factor                                      2.0
  IGHM      immunoglobulin heavy constant mu                                            2.4
  IL4       interleukin 4                                                               3.1
  IL6ST     interleukin 6 signal transducer (gp130, oncostatin M receptor)              2.5
  INSR      insulin receptor                                                            43.5
  IRF4      interferon regulatory factor 4                                              2.1
  KHDRBS1   KH domain containing, RNA binding, signal transduction associated 1         4.6
  LIFR      leukemia inhibitory factor receptor alpha                                   2.5
  LOX       lysyl oxidase                                                               2.3
  LTA       lymphotoxin alpha (TNF superfamily, member 1)                               2.0
  LTB       lymphotoxin beta (TNF superfamily, member 3)                                2.0
  NR3C1     nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)   2.1
  NRG1      neuregulin 1                                                                4.5
  NTF3      neurotrophin 3                                                              2.5
  PIK3R1    phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                     3.5
  PTEN      phosphatase and tensin homolog                                              2.3
  RCAN1     regulator of calcineurin 1                                                  2.9
  SMAD4     SMAD family member 4                                                        3.7
  SOD2      superoxide dismutase 2, mitochondrial                                       3.8
  SPIB      Spi-B transcription factor (Spi-1/PU.1 related)                             2.4
  TRAF4     TNF receptor-associated factor 4                                            2.2
  VEGFA     vascular endothelial growth factor A                                        2.5
  VPREB1    pre-B lymphocyte 1                                                          4.5

Of the genes that were down regulated by AA uniquely in ER+ cells are genes involved in apoptosis such as Caspase 7, Caspase 9, Caspase 10, TNF, and BCL-2 associated agonist of cell death \[[Figure 7](#F0007){ref-type="fig"}\].

![Pathway analysis of genes involved in cell-cell signaling significantly associated with ERbreast cancer cells in response to AA. This cascade was down regulated in ER− cells only. Cells were treated with AA at 6 and 24 hrs. RNA was isolated and hybridized on the cDNA microarray slides as detailed in materials and methods. Images were analyzed using GenePix 6.0 and data were analyzed using GeneSpring 10.1](JC-08-17-g007){#F0007}

The peroxisome proliferator-activated receptor (PPAR) related pathways were significantly down regulated in ER+ cells by Arachidonic acid. These genes are listed in [Table 7](#T0007){ref-type="table"}.

###### 

Peroxisome proliferator-activated receptor (PPAR) pathwaysrelated genes down regulated in ER+ breast cancer cells in Response to AA

  Symbol    Entrez gene name                                                                        Fold change
  --------- --------------------------------------------------------------------------------------- -------------
  ADCY10    adenylate cyclase 10 (soluble)                                                          −3.7
  ASPN      asporin                                                                                 −8.8
  CD36      CD36 molecule (thrombospondin receptor)                                                 −3.9
  CYP2C19   cytochrome P450, family 2, subfamily C, polypeptide 19                                  −9.6
  CYP2C8    cytochrome P450, family 2, subfamily C, polypeptide 8                                   −2.4
  CYP2C9    cytochrome P450, family 2, subfamily C, polypeptide 9                                   −5.9
  FASN      fatty acid synthase                                                                     −2.6
  GH1       growth hormone 1                                                                        −2.9
  GHR       growth hormone receptor                                                                 −21.4
  GNAS      GNAS complex locus                                                                      −15.1
  HRAS      v-Ha-ras Harvey rat sarcoma viral oncogene homolog                                      −2.4
  IKBKB     inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta              −2.3
  IL1R2     interleukin 1 receptor, type II                                                         −4.1
  IL6       interleukin 6 (interferon, beta 2)                                                      −11.8
  KRAS      v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog                                    −2.3
  MAP2K3    mitogen-activated protein kinase kinase 3                                               −3.7
  MAP3K7    mitogen-activated protein kinase kinase kinase 7                                        −2.3
  MED1      mediator complex subunit 1                                                              −2.3
  NCOA3     nuclear receptor coactivator 3                                                          −2.4
  NFKBIE    nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon   −3.8
  PLCE1     phospholipase C, epsilon 1                                                              −2.9
  PLCL1     phospholipase C-like 1                                                                  −31.2
  PRKACA    protein kinase, cAMP-dependent, catalytic, alpha                                        −10.5
  PRKACB    protein kinase, cAMP-dependent, catalytic, beta                                         −4.9
  PRKAR2B   protein kinase, cAMP-dependent, regulatory, type II, beta                               −3.2
  REL       v-rel reticuloendotheliosis viral oncogene homolog (avian)                              −14.7
  RELA      v-rel reticuloendotheliosis viral oncogene homolog A (avian)                            −13.5
  RRAS      related RAS viral (r-ras) oncogene homolog                                              −2.3
  SMAD4     SMAD family member 4                                                                    −3.6

Five genes that were regulated were selected for real-time polymerase chain reaction (PCR). These genes are *Protocadherin, thyroid hormone receptor-associated protein complex component (TRAP150), Mitochondrial ribosomal protein L43, transducer of ERBB2, WNT-2B Isoform 1 oncogene and coiled-coil domain containing 61 (CCDC61).* Real-time PCR was carried out using samples from ER− cells (HCC-1806 and Hs578T) and ER+ cells (CAMA-1 and HCC-70) treated with the fatty acids and compared to the control untreated cells \[[Figure 8](#F0008){ref-type="fig"}\].

![The gene expression data obtained by Real-time PCR experiment. ER− cells (HCC-1806 and Hs578T) and ER+ cells (CAMA-1 and HCC-70) were incubated with either AA (A.) or EPA (B.) for six hours. At the end of the incubation period, the cells were washed with PBS and TriZol was added. Total RNA was isolated analyzed using RT-PCR. Data points are the mean and standard error of three independent experiments for the same samples used in the microarray experiments. Gene expression data were normalized to GAPDH mRNA that showed no regulation among the various treatments compared to the untreated control cells](JC-08-17-g008){#F0008}

DISCUSSION {#sec1-4}
==========

Previous studies have emphasized that the correlation between postmenopausal breast cancer risk and dietary consumption is, for the most part, dependent upon the estrogen receptor status. Scientists have reported that the association between the Alternate Healthy Eating Index (AHEI), the Recommended Food Score (RFS) and the risk of breast cancer were found only in ER− tumors.\[[@CIT12]\]

Many studies focused on the effect of dietary intake of fatty acids and other nutrient on breast cancer. However, a detailed understanding of the correlation between dietary fat intakes and the ER status of breast cancer is not very well achieved.

A study on the association of alcohol intake and breast cancer risk showed no association between alcohol intake and the risk of developing ER− tumors while a statistically significant correlation between alcohol intake and the risk of developing ER+ tumors was observed.\[[@CIT13]\] McCann *et al.* have shown that the anti-tumor effects of dietary lignans, found in flaxseed, sesame seed and oat bran, are limited to ER− breast tumors.\[[@CIT14]\]

A study of the dietary intake of fatty acids in premenopausal breast cancer patients found an association between linoleic acid intake and a higher risk of ER− than ER+ breast tumors.\[[@CIT5]\] The omega-3 fatty acids, EPA and DHA, are shown to inhibit the growth of ER− and ER+ breast cancer cells *in vitro*.\[[@CIT15][@CIT16]\]

In this study, we determine whether the ER status of breast cancer cells plays a role in their responses to fatty acids at the molecular level, using microarrays. We have identified genes and pathways that are differentially expressed between ER− and ER+ cells in response to EPA and AA. The effect of EPA on cell-cell signaling was dependent on the ER status and included the activation of the caspase cascade in ER+ cells while the activation of the Cyclin-dependent kinase cascade was uniquely activated in ER− cells.

Functional interactions between ER and beta-catenin through transcriptional modulation is an important factor for *in vivo* cross-talk of beta-catenin and estrogen signaling pathways. Transcription coactivators and chromatin remodeling complexes that are normally recruited by beta-catenin are shown to interact with ER, and yet ER and beta-catenin are reciprocally recruited to cognate response elements in the promoters of their target genes. This interaction may underlie the pathological conditions in which abnormalities of beta-catenin signaling have been implicated.\[[@CIT17]\] In tumor cells, expression of ER down regulates beta-catenin and its target genes, cyclin D1 and Rb, important regulators of cell cycle and cell proliferation. Over expression of ER induces cellular apoptosis by inducing hTNF-alpha gene expression, which in turn activates caspases -8, -9 and -3 and lead to DNA fragmentation.\[[@CIT18]\]

One of the pathways that were differentially expressed in ER+ cells in response to AA was the ERK/MEK pathway.

For many years, the involvement of the ERK/MEK cascade in cell growth and the prevention of apoptosis have been investigated. Studies have shown that the ERK/MEK pathway can induce the progression of cancer cells due in part to the inhibition of apoptosis.\[[@CIT19]--[@CIT22]\]

It has been well documented that there is cross talk between the ER pathway and the ERK/MEK cascade and that the ERK/MEK pathway is regulated by estrogen in ER+ cells in a Ca+2-dependent manner, and that the anti-apoptotic effect of estrogen may be partly dependent on the ERK/MEK pathway.\[[@CIT23][@CIT24]\]

Arachidonic acid is shown to differentially induce the insulin signaling pathway in ER− cells. Genes involved in insulin receptor signaling pathway such as insulin like growth factors (IGF-I and --II) have been found to induce growth of many breast cancer cells. Expression of IGF-I receptor (IGF-IR) shown to be highly activated in breast tumors in comparison with normal epithelial cells.\[[@CIT25]\] Over expression of insulin receptor signaling genes, which aggravate proliferation of breast cancer cells, is worse in ER− patients. For example, ER− breast cancer patients have higher insulin like growth factor binding proteins levels than ER+ patients.\[[@CIT26]\] Elevated expression of IGF-IR or Insulin receptor substrate 1 (IRS-1) appears to increase drug- and radio-resistance of breast cancer cells and favor cancer recurrence.\[[@CIT25][@CIT27]\] Insulin receptor substrate 1 (IRS-1) is important in transmitting IGF-IR signals to counteract ER apoptotic effect through the PI-3K/Akt survival pathways, and its stabilization improved survival of breast cancer cells in the presence of IGF-I.\[[@CIT28]\]

Also documented is the cross-talk between the PPAR and ER pathways has been documented.\[[@CIT29][@CIT30]\] The PPAR cascade was uniquely down regulated in ER+ cells in response to arachidonic acid and not altered in ER− cells.

Our findings suggest that the ER status of breast cancer cells may play a role in breast cancer cell response to treatments with omega-3 and omega-6 fatty acids.

Further investigation of these pathways may shed light on the importance of the ER status on the mechanistic and therapeutic/preventive roles of fatty acids in breast cancer.

We are grateful to Dena Sumaida and Estelle Ntowe for technical help.
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